There are a total of 12 candidates in mid to late-stage trials for ALS poised to enter the market in the next five years.

Last year, the U.S. Food and Drug Administration approved a drug called tofersen, which can be used in ALS patients with a mutation in a gene called SOD1. This drug is very effective for those ...

There has been a breakthrough in the research on the disease amyotrophic lateral sclerosis (ALS). Scientists at Umeå ...

Qalsody also stabilized patients' quality of life and lowered nerve damage-related biomarkers, consistent with data ...

Leqembi was launched at the start of last year after an accelerated approval for patients with Alzheimer’s and confirmed ...

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004 ...

Amyotrophic lateral sclerosis (ALS) life expectancy varies, but someone diagnosed with ALS is expected to live from two to ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better ...

New RNA-targeted therapy can halt the progression of a specific type of childhood dementia in mice and holds potential to reverse some of the detrimental effects of this rare disease.Scientists from t ...

Discover the groundbreaking patent by Arrowhead Pharmaceuticals Inc for a double-stranded RNA molecule targeting the RRM2 gene. Explore innovative methods for treating gene-related diseases.